Equibles does not estimate personal net worth.
Get an email with a short summary when Enliven Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ELVN alertsBen Hohl is recorded as CFO at Enliven Therapeutics, Inc. (ELVN). The proxy statement of Enliven Therapeutics, Inc. reports total compensation of $3,443,173 for Ben Hohl in fiscal 2025, including a base salary of $480,000. Ben Hohl has spoken on 1 investor event across 1 company, most recently for Enliven Therapeutics, Inc. on June 4, 2026. Enliven Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Enliven Therapeutics, Inc. includes Richard Fair (CEO and Board Member), Rick Fair (CEO and Board Member), Sam Kintz, M.B.A. (CEO and Board Member) and 7 others.
“I think we also want to make the point that even that 50% that people are honing in on is still kind of an unknown number.”
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Enliven Therapeutics, Inc. (ELVN) | Chief Financial Officer | $480,000 | $3,443,173 |
